Literature DB >> 22676853

Calcium phosphatase calcineurin influences tau metabolism.

Celeste M Karch1, Amanda T Jeng, Alison M Goate.   

Abstract

Alzheimer's disease (AD) is characterized by neuronal loss and the accumulation of β-amyloid plaques and neurofibrillary tangles in the brain. Cerebrospinal fluid (CSF) levels of β-amyloid and tau/phospho-tau 181 (ptau 181) are also associated with AD. We have previously demonstrated that a single nucleotide polymorphism in calcineurin is associated with CSF ptau 181 levels and AD progression. In this study, we demonstrate that calcineurin protein levels are inversely correlated with dementia severity and Braak tangle stage in AD brains, and calcineurin activity is globally reduced in AD brains. We then sought to model the observed changes in CSF tau by measuring extracellular tau in cultured cells. SH-SY5Y cells treated with calcineurin inhibitors produced reduced calcineurin activity and a corresponding increase in extracellular ptau 181. These findings are consistent with our observations in AD patients, who have elevated CSF ptau 181 and reduced calcineurin activity in brain extracts. Thus, we have identified a gene that contributes to AD pathology and has functional consequences on tau metabolism in cultured cells.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22676853      PMCID: PMC3879081          DOI: 10.1016/j.neurobiolaging.2012.05.003

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  48 in total

1.  Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

Authors:  C Hesse; L Rosengren; N Andreasen; P Davidsson; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Neurosci Lett       Date:  2001-01-19       Impact factor: 3.046

2.  Inducible and reversible enhancement of learning, memory, and long-term potentiation by genetic inhibition of calcineurin.

Authors:  G Malleret; U Haditsch; D Genoux; M W Jones; T V Bliss; A M Vanhoose; C Weitlauf; E R Kandel; D G Winder; I M Mansuy
Journal:  Cell       Date:  2001-03-09       Impact factor: 41.582

3.  Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease.

Authors:  N Itoh; H Arai; K Urakami; K Ishiguro; H Ohno; H Hampel; K Buerger; J Wiltfang; M Otto; H Kretzschmar; H J Moeller; M Imagawa; H Kohno; K Nakashima; S Kuzuhara; H Sasaki; K Imahori
Journal:  Ann Neurol       Date:  2001-08       Impact factor: 10.422

4.  Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory.

Authors:  H Zeng; S Chattarji; M Barbarosie; L Rondi-Reig; B D Philpot; T Miyakawa; M F Bear; S Tonegawa
Journal:  Cell       Date:  2001-11-30       Impact factor: 41.582

Review 5.  Calcineurin: form and function.

Authors:  F Rusnak; P Mertz
Journal:  Physiol Rev       Date:  2000-10       Impact factor: 37.312

Review 6.  Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia.

Authors:  Harald Hampel; Stefan J Teipel
Journal:  Dement Geriatr Cogn Disord       Date:  2004       Impact factor: 2.959

7.  Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex.

Authors:  Q Lian; C J Ladner; D Magnuson; J M Lee
Journal:  Exp Neurol       Date:  2001-01       Impact factor: 5.330

8.  Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.

Authors:  R Kohnken; K Buerger; R Zinkowski; C Miller; D Kerkman; J DeBernardis; J Shen; H J Möller; P Davies; H Hampel
Journal:  Neurosci Lett       Date:  2000-06-30       Impact factor: 3.046

9.  Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

Authors:  Katharina Buerger; Raymond Zinkowski; Stefan J Teipel; Tero Tapiola; Hiroyuki Arai; Kaj Blennow; Niels Andreasen; Klaus Hofmann-Kiefer; John DeBernardis; Daniel Kerkman; Cheryl McCulloch; Russell Kohnken; Frank Padberg; Tuula Pirttilä; Marc B Schapiro; Stanley I Rapoport; Hans-Jürgen Möller; Peter Davies; Harald Hampel
Journal:  Arch Neurol       Date:  2002-08

10.  Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease.

Authors:  T Chris Gamblin; Feng Chen; Angara Zambrano; Aida Abraha; Sarita Lagalwar; Angela L Guillozet; Meiling Lu; Yifan Fu; Francisco Garcia-Sierra; Nichole LaPointe; Richard Miller; Robert W Berry; Lester I Binder; Vincent L Cryns
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-29       Impact factor: 11.205

View more
  21 in total

Review 1.  The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

Authors:  Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2014-05-21       Impact factor: 17.173

2.  Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway.

Authors:  V R Varma; S Varma; Y An; T J Hohman; S Seddighi; R Casanova; A Beri; E B Dammer; N T Seyfried; O Pletnikova; A Moghekar; M R Wilson; J J Lah; R J O'Brien; A I Levey; J C Troncoso; M S Albert; M Thambisetty
Journal:  Mol Psychiatry       Date:  2016-11-22       Impact factor: 15.992

3.  TDP-43 expression influences amyloidβ plaque deposition and tau aggregation.

Authors:  Stephani A Davis; Kok Ann Gan; James A Dowell; Nigel J Cairns; Michael A Gitcho
Journal:  Neurobiol Dis       Date:  2017-04-20       Impact factor: 5.996

Review 4.  Alzheimer's disease genetics: from the bench to the clinic.

Authors:  Celeste M Karch; Carlos Cruchaga; Alison M Goate
Journal:  Neuron       Date:  2014-07-02       Impact factor: 17.173

Review 5.  A central role for calcineurin in protein misfolding neurodegenerative diseases.

Authors:  Syed Zahid Ali Shah; Tariq Hussain; Deming Zhao; Lifeng Yang
Journal:  Cell Mol Life Sci       Date:  2016-09-28       Impact factor: 9.261

6.  Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies.

Authors:  Celeste M Karch; Amanda T Jeng; Alison M Goate
Journal:  J Biol Chem       Date:  2012-10-26       Impact factor: 5.157

7.  A Functional Role for the Epigenetic Regulator ING1 in Activity-induced Gene Expression in Primary Cortical Neurons.

Authors:  Laura J Leighton; Qiongyi Zhao; Xiang Li; Chuanyang Dai; Paul R Marshall; Sha Liu; Yi Wang; Esmi L Zajaczkowski; Nitin Khandelwal; Arvind Kumar; Timothy W Bredy; Wei Wei
Journal:  Neuroscience       Date:  2017-11-20       Impact factor: 3.590

8.  Local Inhibition of PERK Enhances Memory and Reverses Age-Related Deterioration of Cognitive and Neuronal Properties.

Authors:  Vijendra Sharma; Hadile Ounallah-Saad; Darpan Chakraborty; Mohammad Hleihil; Rapita Sood; Iliana Barrera; Efrat Edry; Sailendrakumar Kolatt Chandran; Shlomo Ben Tabou de Leon; Hanoch Kaphzan; Kobi Rosenblum
Journal:  J Neurosci       Date:  2017-12-01       Impact factor: 6.167

9.  Calcineurin proteolysis in astrocytes: Implications for impaired synaptic function.

Authors:  Melanie M Pleiss; Pradoldej Sompol; Susan D Kraner; Hafiz Mohmmad Abdul; Jennifer L Furman; Rodney P Guttmann; Donna M Wilcock; Peter T Nelson; Christopher M Norris
Journal:  Biochim Biophys Acta       Date:  2016-05-20

10.  Integrative genomic analysis of PPP3R1 in Alzheimer's disease: a potential biomarker for predictive, preventive, and personalized medical approach.

Authors:  Chuansheng Zhao; Mei Zhao; Zhike Zhou; Jun Bai; Shanshan Zhong; Rongwei Zhang; Kexin Kang; Xiaoqian Zhang; Ying Xu
Journal:  EPMA J       Date:  2021-11-15       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.